Refreshing results…
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
UploadAdipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH
UploadGlobal survey of stigma among physicians and patients with nonalcoholic fatty liver disease
UploadA global research priority agenda to advance public health responses to fatty liver disease
UploadNon-invasive tests for clinically significant portal hypertension after HCV cure
UploadMicrobiome-derived ethanol in nonalcoholic fatty liver disease
Download from www.nature.comPosttranscriptional Regulation of the Human LDL Receptor by the U2-Spliceosome
UploadA Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
UploadTwo-dimensional shear wave elastography predicts survival in advanced chronic liver disease
UploadNon-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis
Download from doi.orgMissing publications? Search for publications with a matching author name.